Solence Secures €1.6M Seed Funding for AI-Driven PCOS Care

Paris-based FemTech startup Solence has secured €1.6 million in Seed funding. This round was led by Impact Shakers Ventures. The investment advances its AI-driven digital therapeutics app for Polycystic Ovary Syndrome (PCOS).

Solence, founded by Clara Stephenson in 2022, offers a patient app. This app provides personalized lifestyle interventions to manage PCOS symptoms. Furthermore, it leverages data insights to reshape healthcare delivery for the condition.

Advancing AI-Driven PCOS Therapeutics

PCOS affects up to 20% of women globally; however, many lack adequate support. Current routine care often relies on pharmacotherapy. Evidence-based guidelines prioritize lifestyle and behavioral interventions for therapeutic benefits. Solence addresses this critical gap.

The app's twelve-week program combines biomedical knowledge with habit-formation science. It provides interactive lessons and monthly assessment scores.

This FemTech funding highlights growing interest in women's health technology. Other notable FemTech players include Hormona, focusing on hormone tracking, and Flo Health, a popular period tracker. Solence specifically targets PCOS management, a distinct area within AI healthcare startups.

Angel investors include Céline Lazorthes, Berthe Latreille, Stephane Mardel, and BPI France. Solence plans to deepen product functionality and expand its team. Additionally, the funds will strengthen clinical partnerships and support distribution strategies for its digital therapeutics.